RPTX stock gains as Roche signs licensing deal for tumor candidate (NASDAQ:RPTX)
seekingalpha.com
finance
2022-06-01 20:20:10

Eoneren/E+ via Getty Images Repare Therapeutics (NASDAQ:RPTX) climbed ~17% in the post-market Wednesday after the clinical-stage precision oncology company announced a worldwide license and collaboration agreement with Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) for its leading cancer candidate RP-3500. The oral experimental drug also known as camonsertib is designed to target tumors with specific genetic mutations including those in the ATM gene. Per the terms, Roche (OTCQX:RHHBY) will take over the development of RP-3500 with potential to expand its studies into additional tumors and combination therapeutic regimens.
